Teva draws blank in phase 3 Tourette Syndrome trialTeva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the Share XTeva draws blank in phase 3 Tourette Syndrome trialhttps://pharmaphorum.com/news/teva-draws-blank-in-phase-3-tourette-syndrome-trial/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
Chasing Astellas, UK’s KaNDy heads to phase 3 with menopause drugUK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial Share XChasing Astellas, UK’s KaNDy heads to phase 3 with menopause drughttps://pharmaphorum.com/news/chasing-astellas-uks-kandy-heads-to-phase-3-with-menopause-drug/
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drugSwiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop Share XNeurocrine signs $400M-plus deal with Idorsia for epilepsy drughttps://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/
FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
